Longitudinal changes of CSF biomarkers in alzheimer's disease

Journal of Alzheimer's Disease

Volumn 25, Issue 4, 2011, Pages 583-594

  Seppälä, Toni T ^a   Koivisto, Anne M ^a,b   Hartikainen, Päivi ^b   Helisalmi, Seppo ^a   Soininen, Hilkka ^a,b   Herukka, Sanna Kaisa ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Alzheimer's disease; amyloid; biomarker; cerebrospinal fluid; CSF; longitudinal; mild cognitive impairment; tau

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; BIOLOGICAL MARKER; P TAU PROTEIN 181; TAU PROTEIN; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; COGNITION; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROLOGIC DISEASE; NEUROPATHOLOGY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

EID: 80052846251     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-101911     Document Type: Article

References (40)

1. Price JL, Morris JC (1999) Tangles and plaques in nonde-mented aging and "preclinical" Alzheimer's disease. Ann Neurol 45, 358-368. (Pubitemid 29120041)
2. Glenner GG, Wong CW (1984) Alzheimer's disease: initial report of the purification and characterization of a novel cere-brovascular amyloid protein. Biochem Biophys Res Commun 120, 885-890. (Pubitemid 14104991)
3. Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM (1986) Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem 261, 6084-6089. (Pubitemid 17207447)
4. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI (1986) Abnormal phos-phorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 83, 4913-4917.
5. Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, Shen Y, Dodel R, Du Y, Farlow M, Moller HJ, Blennow K, Buerger K (2004) Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry 9, 705-710. (Pubitemid 38932175)
6. Herukka SK, Hallikainen M, Soininen H, Pirttila T (2005) CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology 64, 1294-1297.
7. Dubois B, Feldman HH, Jacova C, DeKosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6, 734-746. (Pubitemid 47058377)
8. Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, Vanderstichele H, Vanmechelen E, Blennow K (1999) Cerebrospinal fluid beta-amyloid (1-42) in Alzheimer disease: differences between early-and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 56, 673-680. (Pubitemid 29266465)
9. Andreasen N, Minthon L, Vanmechelen E, Vanderstichele H, Davidsson P, Winblad B, Blennow K (1999) Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci Lett 273, 5-8. (Pubitemid 29415689)
10. Sunderland T, Wolozin B, Galasko D, Levy J, Dukoff R, Bahro M, Lasser R, Motter R, Lehtimaki T, Seubert P (1999) Longitudinal stability of CSF tau levels in Alzheimer patients. Biol Psychiatry 46, 750-755. (Pubitemid 29460900)
11. Tapiola T, Pirttila T, Mikkonen M, Mehta PD, Alafuzoff I, Koivisto K, Soininen H (2000) Three-year follow-up of cere-brospinal fluid tau, beta-amyloid 42 and 40 concentrations in Alzheimer's disease. Neurosci Lett 280, 119-122. (Pubitemid 30109147)
12. Mollenhauer B, Bibl M, Trenkwalder C, Stiens G, Cepek L, Steinacker P, Ciesielczyk B, Neubert K, Wiltfang J, Kretzschmar HA, Poser S, Otto M (2005) Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimer's disease. J Neural Transm 112, 933-948. (Pubitemid 40869082)
13. Hoglund K, Thelen KM, Syversen S, Sjogren M, von Bergmann K, Wallin A, Vanmechelen E, Vanderstichele H, Lutjohann D, Blennow K (2005) The effect of simvas-tatin treatment on the amyloid precursor protein and brain cholesterol metabolism in patients with Alzheimer's disease. Dement Geriatr Cogn Disord 19, 256-265. (Pubitemid 40663319)
14. de Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, Rusinek H, Li J, Tsui W, Saint Louis LA, Clark CM, Tarshish C, Li Y, Lair L, Javier E, Rich K, Lesbre P, Mosconi L, Reisberg B, Sadowski M, DeBernadis JF, Kerkman DJ, Hampel H, Wahlund LO, Davies P (2006) Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging 27, 394-401. (Pubitemid 43185324)
15. Sluimer JD, Bouwman FH, Vrenken H, Blankenstein MA, Barkhof F, van der Flier WM, Scheltens P (2010) Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: A longitudinal study. Neurobiol Aging 31, 758-764.
16. Bouwman FH, van der Flier WM, Schoonenboom NSM, van Elk EJ, Kok A, Rijmen F, Blankenstein MA, Scheltens P (2007) Longitudinal changes of CSF biomarkers in memory clinic patients. Neurology 69, 1006-1011. (Pubitemid 47366054)
17. Andersson C, Blennow K, Almkvist O, Andreasen N, Engfeldt P, Johansson S, Lindau M, Eriksdotter-Jönhagen M (2008) Increasing CSF phospho-tau levels during cognitive decline and progression to dementia. Neurobiol Aging 29, 1466-1473.
18. Brys M, Pirraglia E, Rich K, Rolstad S, Mosconi L, Switalski R, Glodzik-Sobanska L, De Santi S, Zinkowski R, Mehta P, Pratico D, Saint Louis LA, Wallin A, Blennow K, de Leon MJ (2009) Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol Aging 30, 682-690.
19. Stomrud E, Hansson O, Zetterberg H, Blennow K, Minthon L, Londos E (2010) Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. Arch Neurol 67, 217-223.
20. Beckett LA, Harvey DJ, Gamst A, Donohue M, Kornak J, Zhang H, Kuo JH, Alzheimer's Disease Neuroimaging Initiative (2010) The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes. Alzheimers Dement 6, 257-264.
21. Kanai M, Matsubara E, Isoe K, Urakami K, Nakashima K, Arai H, Sasaki H, Abe K, Iwatsubo T, Kosaka T, Watanabe M, Tomidokoro Y, Shizuka M, Mizushima K, Nakamura T, Igeta Y, Ikeda Y, Amari M, Kawarabayashi T, Ishiguro K, Harigaya Y, Wakabayashi K, Okamoto K, Hirai S, Shoji M (1998) Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42 (43) in Alzheimer's disease: a study in Japan. Ann Neurol 44, 17-26. (Pubitemid 28323651)
22. Wahlund LO, Blennow K (2003) Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients. Neurosci Lett 339, 99-102. (Pubitemid 36254786)
23. Andreasen N, Vanmechelen E, Van de Voorde A, Davids-son P, Hesse C, Tarvonen S, Raiha I, Sourander L, Winblad B, Blennow K (1998) Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based followupstudy. J Neurol Neurosurg Psychiatry64, 298-305. (Pubitemid 28159831)
24. Blomberg M, Jensen M, Basun H, Lannfelt L, Wahlund LO (1996) Increasing cerebrospinal fluid tau levels in a subgroup of Alzheimer patients with apolipoprotein E allele epsilon 4 during 14 months follow-up. Neurosci Lett 214, 163-166. (Pubitemid 26284457)
25. Isoe K, Urakami K, Shimomura T, Wakutani Y, Ji Y, Adachi Y, Takahashi K (1996) Tau proteins in cerebrospinal fluid from patients with Alzheimer's disease: a longitudinal study. Dementia 7, 175-176. (Pubitemid 26125798)
26. Kanai M, Shizuka M, Urakami K, Matsubara E, Harigaya Y, Okamoto K, Shoji M (1999) Apolipoprotein E4 accelerates dementia and increases cerebrospinal fluid tau levels in Alzheimer's disease. Neurosci Lett 267, 65-68. (Pubitemid 29251624)
27. Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, Mintun MA (2010) APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 67, 122-131.
28. Herukka SK, Helisalmi S, Hallikainen M, Tervo S, Soininen H, Pirttila T (2007) CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI. Neurobiol Aging 28, 507-514.
29. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B (2001) Current concepts in mild cognitive impairment. Arch Neurol58, 1985-1992. (Pubitemid 33143977)
30. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944. (Pubitemid 14076461)
31. Tsukamoto K, Watanabe T, Matsushima T, Kinoshita M, Kato H, Hashimoto Y, Kurokawa K, Teramoto T (1993) Determination by PCR-RFLP of apo E genotype in a Japanese population. J Lab Clin Med 121, 598-602. (Pubitemid 23112654)
32. Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, Thomas R, Kholodenko D, Schenk D, Lieberburg I, Miller B, Green R, Basherad R, Kertiles L, Boss MA, Seubert P (1998) High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neu-rol 55, 937-945. (Pubitemid 28335112)
33. Prince JA, Zetterberg H, Andreasen N, Marcusson J, Blennow K (2004) APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42. Neurology 62, 2116-2118. (Pubitemid 38738236)
34. Vemuri P, Wiste HJ, Weigand SD, Knopman DS, Shaw LM, Trojanowski JQ, Aisen PS, Weiner M, Petersen RC, Jack CR Jr, Alzheimer's Disease Neuroimaging Initiative (2010) Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann Neurol 67, 308-316.
35. Wallin AK, Blennow K, Zetterberg H, Londos E, Minthon L, Hansson O (2010) CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology 74, 1531-1537.
36. Snider BJ, Fagan AM, Roe C, Shah AR, Grant EA, Xiong C, Morris JC, Holtzman DM (2009) Cerebrospinal fluid biomarkers and rateofcognitive declineinverymild dementia of the Alzheimer type. Arch Neurol 66, 638-645.
37. Vemuri P, Wiste HJ, Weigand SD, Knopman DS, Trojanowski JQ, Shaw LM, Bernstein MA, Aisen PS, Weiner M, Petersen RC, Jack CRJr, Alzheimer's Disease Neuroimaging Initiative (2010) Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology 75, 143-151.
38. Iqbal K, Flory M, Khatoon S, Soininen H, Pirttila T, Lehtovirta M, Alafuzoff I, Blennow K, Andreasen N, Vanmechelen E, Grundke-Iqbal I (2005) Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers. Ann Neurol 58, 748-757. (Pubitemid 41552550)
39. Jack CR Jr, Wiste HJ, Vemuri P, Weigand SD, Senjem ML, Zeng G, Bernstein MA, Gunter JL, Pankratz VS, Aisen PS, Weiner MW, Petersen RC, Shaw LM, Trojanowski JQ, Knopman DS, Alzheimer's Disease Neuroimaging Initiative (2010) Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain 133, 3336-3348.
40. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9, 119-128.